Investigational Site Number :3800003

Rozzano, Milano 20089

2 studies enrolling now · 10 studies all time

What they study most

Asthma, Breast Cancer, Chronic Obstructive Pulmonary Disease, Colitis Ulcerative, Hemophilia, Malignant Solid Tumor, Neoplasm, Non-small Cell Lung Cancer, Prostate Cancer

Studies at this site

• A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B — Recruiting now
• A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis — Recruiting now
• Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma — Running, not enrolling
• Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia — Running, not enrolling
• Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer — Stopped early
• A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors — Completed
• Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation — Completed
• Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies — Stopped early
• Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies — Stopped early